✨ Free AI Report
CARGO Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research CARGO Therapeutics, Inc.
Company Research

CARGO Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

CARGO Therapeutics is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer patients. The company advances next-generation cell thera...

Analyst-debate audio for CARGO Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for CARGO Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
2/ 10Challenged

Cyborg Score thesis

Development setback and massive downsizing present material execution risk despite previously strong cash...

Read the full analyst-debate transcript →
Industry Biotechnology - Cell Therapy / Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest CARGO Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

CARGO Therapeutics, Inc. Overview

Pro stress-test →

CARGO Therapeutics is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer patients. The company advances next-generation cell therapies designed to overcome limitations of existing approved CAR T treatments, addressing challenges like tumor antigen loss, T-cell exhaustion, and treatment resistance.

Strategic Profile

Pro stress-test →

The company's lead program CRG-023 is a tri-specific CAR T designed to target multiple B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector. CARGO continues advancing CRG-023 into Phase 1 trials and is developing its allogeneic platform while evaluating strategic options.

Competitive Landscape

Pro stress-test →

Kyverna and Allogene Therapeutics are competitors of CARGO Therapeutics. The CAR T-cell therapy space is highly competitive with established players like Kite Pharma, Juno Therapeutics, and emerging companies addressing treatment-resistant cancers. CARGO's competitive positioning has weakened substantially following the clinical trial discontinuation.

Industry Context

CARGO Therapeutics, Inc. operates in Biotechnology - Cell Therapy / Oncology.

Key facts

Founded: 2019 · Headquarters: San Carlos, CA · Employees: 102 · Revenue: $0 · Market cap: $216M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on CARGO Therapeutics, Inc..

  • Lead program (firi-cel) discontinued due to unfavorable benefit-risk profile with severe safety signals; company pivoting focus to CRG-023
  • Executed drastic workforce reduction from initial 50% down to 90% RIF, indicating preserved cash runway through 2028 but reduced operational capacity
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2025Announced further 90% workforce reduction following firi-cel program suspension
  • January 2025Discontinued FIRCE-1 Phase 2 study due to safety concerns; 50% workforce reduction announced
  • +1 moreTrack every material event for CARGO Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when CARGO Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Allogene TherapeuticsAllogeneic CAR T-cell therapies for cancer→KyvernaCAR T-cell therapy developer→Juno TherapeuticsCell therapy platform including CAR T→

Compare CARGO Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CARGO Therapeutics, Inc. operates in Biotechnology - Cell Therapy / Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Cell Therapy / Oncology research →
NEW · MCP server

Ask your AI assistant about CARGO Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CARGO Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did CARGO Therapeutics, Inc. do this quarter?”
“Is CARGO Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does CARGO Therapeutics, Inc. do?+
CARGO Therapeutics is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer patients. The company advances next-generation cell thera...
What is CARGO Therapeutics, Inc.'s Cyborg Score?+
CARGO Therapeutics, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CARGO Therapeutics, Inc.'s main competitors?+
Named competitors include Allogene Therapeutics, Kyverna, Juno Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full CARGO Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CARGO Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CARGO Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Cell Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Cartesian Therapeutics, Inc.